Predicting the risk of prostate cancer recurrence through the lens of evolution

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-07-23 DOI:10.1038/s43018-024-00792-3

引用次数: 0

Abstract

Current prostate cancer risk predictors are not able to fully capture a patient’s risk of recurrence at the time of diagnosis. Evolutionary metrics of tumor diversity, based on low-cost sequencing and digital pathology, might provide a new dimension of information to close the gap between prediction and outcome.

Abstract Image

查看原文本刊更多论文

从进化的角度预测前列腺癌复发的风险。

目前的前列腺癌风险预测指标无法完全反映患者在诊断时的复发风险。基于低成本测序和数字病理学的肿瘤多样性进化指标可能会提供新的信息维度，缩小预测与结果之间的差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.